Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023